APRIL 2019 NEWS IN PARKINSON’S​

Journal of Parkinson’s Disease

 

While PD has traditionally regarded as a neuromotor disorder, it is not known to be a heterogeneous multisystem disorder- in recognition of the significant impact that non-motor symptoms have on the quality of life of individuals affected by PD. Up to 57% of patients suffering from PD develop mild cognitive impairment within 5 years of their initial diagnosis and, if they survive more than 10 years, the majority will eventually develop dementia. The underlying neurophysiological mechanisms are not completely understood, but an accumulation of amyloid plaques, mitochondrial dysfunction and neurotransmitter changes are all suggested to contribute.

Literature review suggests that potential of aerobic exercise to improve motor and non-motor symptoms is promising and may help to decelerate the disease progression.

 

Journal of Parkinson’s Disease

Study that looked at boosting levels of a naturally occurring growth factor, Gliia Cell Line-Derived Neurotropic Factor (GDNF) can regenerate dying dopamine brain cells in patents with PD and reverse their condition. Utilizing an infusion process, after 9 months the group who received GDNF showed an improvement of 100% in a key area of the brain affected offering hope that the treatment was starting to reawaken and restore brain cells. This is a significant breakthrough because most drugs that might work cannot cross from the blood stream into the brain due to a natural protective barrier. 

 

COMPASSIONATE, EFFECTIVE, AFFORDABLE CARE